The US-China Yoshiwa (02453) rose by more than 10% and rose 10.66% at press time to HK$23.35, with a turnover of HK$1.74 million.
The Zhitong Finance App learned that the US and China Jiahe (02453) rose by more than 10% and rose 10.66% at press time to HK$23.35, with a turnover of HK$1.74 million. Since its listing, the company's stock price has been rising, with a cumulative increase of nearly 100% up to now.
According to reports, the company is an oncology medical service provider. Its main business includes operating hospitals and medical equipment, software and related services for third-party medical institutions. In the first half of 2023, these two businesses accounted for 55.8% and 44.2% of the company's revenue, respectively. The company's hospital business has a total of seven medical institutions, mainly located in densely populated cities such as Guangzhou, Shanghai and Shanxi. According to the Frost & Sullivan report, China's oncology medical services market increased by 495.1 billion yuan from about 265.6 billion yuan in 2016 to 495.1 billion yuan, a CAGR of 10.9%.
Sino-Thai International anticipates that demand for cancer treatment will increase in the future, and the situation where public medical resources are in short supply in some cities will be difficult to improve in the short term, so high-quality private oncology medical institutions will benefit. Due to insufficient equipment and technical standards in some small and medium-sized hospitals, the government is also encouraging the improvement of the diagnostic and treatment capabilities of primary hospitals, so the demand for equipment and technical support will increase in the long run.